TLR2 modulator compounds, pharmaceutical compositions and uses thereof

A method for treating cancer in a subject in need thereof, comprising administering to the subject a compound of Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• R is:
• wherein each R is substituted or unsubstituted;
• or
• R is
• L1 is a five-membered heteroarylene, or a bond;
• G is:
• X is —NH(CH2)m CH3, —NH(CH2)m-(substituted or unsubstituted Ph), or
• Z is CH or N, provided that no more than one Z on any one ring is N;
• each Z1 is independently —CH2— or —C(═O)—;
• each Z2 is independently —O—, —S—, or —NH—;
• L2 is a bond, —(CH2)m—, —CO—, —SO2—, —(C═O)NH—, or —(C═O)O—;
• Y is —H, substituted or unsubstituted C1-16 alkyl, C1-16 alkyl-(substituted or unsubstituted Ph), —NH(CH2)mCH3, —SO2(CH2)13CH3, or substituted or unsubstituted C3-10 cycloalkyl;
• W is H, hydroxyl, —OCH3, —O(CH2)mCH3, —NH(C═O)CH3—NH(C═O)(CH2)mCH3, —(C═O)—NH(CH2)mCH3, substituted or unsubstituted C1-16 alkyl, C1-16 alkyl-(substituted or unsubstituted Ph), —NH(CH2)mCH3, —N((CH2)mCH3)2, —N(CH3)(Y), or substituted or unsubstituted C3-10 cycloalkyl;
• each m is independently 1-16;
• each n is independently 1-3;
• and
• each p is independently 3-8.